Astonea Labs Ltd has announced a strategic restructuring, including the formation of a new subsidiary, Longevity Science Private Limited, and a USD 10,000 investment in its US-based entity, Astonea LLC. Simultaneously, the company has officially terminated its material supply and brand licensing agreements with Astonea One Private Limited. These moves represent a shift in operational focus, as the board also finalized its internal audit appointments for the upcoming fiscal year.
Astonea Labs Announces Strategic Restructuring and US Expansion
Astonea Labs confirms the formation of Longevity Science Private Limited and USD 10,000 overseas investment.
Agreements with Astonea One Private Limited are terminated effective immediately.
Reader Takeaway: Expansion into new markets balanced against potential operational shifts from terminated legacy manufacturing and supply agreements.
What just happened
The board of Astonea Labs approved the incorporation of 'Longevity Science Private Limited,' where it intends to hold a majority stake of at least 51%. The company is currently rectifying a spelling error in the name filed with the Registrar of Companies. Additionally, the board cleared an overseas direct investment (ODI) of up to USD 10,000 for its wholly-owned subsidiary, Astonea LLC, located in Wyoming, USA.
Why this matters
The immediate termination of the Material Supply & Manufacturing Agreement and the Distribution, Marketing & Brand License Agreement with Astonea One Private Limited signals a clean break from previous operational partnerships. This decision supersedes earlier deferral plans and indicates a change in how Astonea Labs will handle its manufacturing and distribution pipelines moving forward.
The backstory
The company had previously considered deferring its decision regarding these agreements on July 24, 2026. The current board meeting has solidified the decision to revoke all rights previously granted under those specific pacts.
Audit and Governance
The board reviewed the Cost Audit Report for the fiscal year ending March 31, 2026, prepared by M/s. Balwinder & Associates, which showed no adverse remarks or qualifications. Mr. Chander Shekhar has been appointed as the Internal Auditor for FY 2026-27 to oversee governance standards.
What to track next
Investors should look for disclosures regarding the impact of the terminated agreements on near-term manufacturing volumes and how the new US-based subsidiary contributes to the company's revenue stream in coming quarters.